Stanford BMT-CT ASH Abstracts 2022: Oral Abstracts

265 Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
Caspian Oliai, MD, MS1, Rasmus T Hoeg, MD2*, Anna Pavlova, MD, PhD3*, Arpita Gandhi, MD4, Lori Muffly, MD5, Rohtesh S. Mehta, MD6, Samer A Srour, MD, MS7, Edmund K. Waller, MD, PhD8, Robert Lowsky, MD9, Sagar S. Patel, MD10, Bhagirathbhai Dholaria, MBBS11, Carlos Bachier, MD12, Jeremy M. Pantin, MD, FACP13, Amandeep Salhotra, MD14, Joseph P. McGuirk, DO15, Nathaniel B Fernhoff, PhD16*, J Scott McClellan, MD, PhD16, Mehrdad Abedi, MD2, Robert S. Negrin, MD9 and Everett H Meyer, MD, PhD9*
https://ash.confex.com/ash/2022/webprogram/Paper165654.html

640 Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA
Hitomi Hosoya, MD, PhD1, Mia Carleton2*, Kailee L Tanaka2*, Brian Sworder, MD, PhD3, Vanna Hovanky4*, George E Duran, BA2*, Tian Y. Zhang, MD, PhD5, Michael S. Khodadoust, MD PhD2, David B. Miklos, MD, PhD4, Sally Arai, MD6, David Iberri, MD2, Michaela Liedtke, MD2, Surbhi Sidana, MD7 and David M. Kurtz, MD, PhD1
https://ash.confex.com/ash/2022/webprogram/Paper160370.html

982 CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study
Nikeshan Jeyakumar, MD1, Sneha Ramakrishna, MD2, Matthew J Frank, MD, PhD3, Bita Sahaf, PhD4*, Steven A. Feldman, PhD4*, David B. Miklos, MD, PhD5, Crystal L. Mackall, MD6, Kara L. Davis, D.O.7, Lori Muffly, MD, MS8 and Liora M. Schultz, MD9
https://ash.confex.com/ash/2022/webprogram/Paper164456.html

543 Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
Brian Sworder, MD, PhD1, David M. Kurtz, MD, PhD1, Stefan K. Alig, MD2, Matthew J Frank, MD, PhD3, Navika D. Shukla, MD4*, Andrea Garofalo5*, Charles Macaulay, MSc, BA5*, Mohammad Shahrokh Esfahani, PhD2*, Mari Olsen2*, James Hamilton III6*, Hitomi Hosoya, MD, PhD6, Mark P Hamilton, MD7, Jay Y. Spiegel, MD, FRCPC8, John H. Baird, MD8, Mia Carleton2*, Alexander F. M. Craig, MD, MPhil9, Sheren F. Younes, MD, PhD10*, Bita Sahaf, PhD8*, Natasha Sheybani, PhD1*, Joseph Schroers-Martin, MD6, Chih Long Liu, PhD6*, Jean S Oak, MD, PhD10*, Michael C. Jin6*, Sara Beygi, MD11, Andreas Hüttmann, MD12, Christine Hanoun13*, Ulrich Dührsen, Prof, MD, PhD13*, Jason Westin, MD14, Michael S. Khodadoust, MD PhD15, Yasodha Natkunam, MD, PhD16, Robbie G. Majzner, MD17, Crystal L. Mackall, MD18,19, Maximilian Diehn, MD, PhD20*, David B. Miklos, MD, PhD8 and Ash A. Alizadeh, MD, PhD21
https://ash.confex.com/ash/2022/webprogram/Paper165545.html

720 Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation
Emily C. Liang, MD1, Simone E. Dekker, MD, PhD2, Jean M.G. Sabile, MD3, Stefan Torelli, MD4*, Amy Zhang, MPH5*, Katharine Miller, PhD5*, Parveen Shiraz, MD6, Brandon Hayes-Lattin, MD7, Jessica Leonard, MD7 and Lori Muffly, MD6
https://ash.confex.com/ash/2022/webprogram/Paper157442.html

994 Geographical Barriers to Accessing Specialty Cancer Care Among Adolescents and Young Adults with Acute Lymphoblastic Leukemia
Lori Muffly, MD, MS1, Ariadna Garcia2*, Katharine Miller, PhD2*, Theresa H.M. Keegan, PhD3 and Helen Parsons, PhD MPH4*
https://ash.confex.com/ash/2022/webprogram/Paper163840.html

110 Multi-Omics Profiling of Skin Biopsies of Patients with Sclerodermatous Graft-Vs-Host Disease Suggests Therapeutic Potential of Targeting Don't Eat Me Signals
Lu Cui1*, Cristabelle De Souza, Ph.D.1*, Tristan Lerbs1*, Jessica Poyser1*, Clarissa Yu2*, Kerri Rieger, MD PhD3*, Sally Arai, MD4, Ryanne Brown5*, Judith A Shizuru, MD, PhD6, Antonia Maria Susanne Müller7* and Gerlinde Wernig, MD8
https://ash.confex.com/ash/2022/webprogram/Paper169789.html

765 Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy
Matthew A. Lunning, DO, FACP1, Hai-Lin Wang, MPH2*, Zhen-Huan Hu, MPH2*, Frederick L. Locke, MD3, Tanya Siddiqi, MD4, Caron A. Jacobson, MD5, Sairah Ahmed, MD6, David B. Miklos, MD, PhD7, Yi Lin, MD, PhD8, Brian T. Hill, MD, PhD9, Armin Ghobadi, MD10, Sattva S. Neelapu, MD11, Jason Westin, MD12, Harry Miao, MD, PhD2*, Shilpa Shahani, MD2*, Anik R. Patel, PhD2*, Clare Spooner, MBBS, BSc2*, Christine Fu, PhD2*, Hairong Xu, MD, PhD2* and Marcelo C Pasquini, MD, MS13

659 Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study
Armin Ghobadi, MD1, Javier Munoz, MD, MS, MBA2, Jason Westin, MD3, Frederick L. Locke, MD4, David B. Miklos, MD, PhD5, Aaron P. Rapoport, MD6, Miguel-Angel Perales, MD7, Patrick M. Reagan, MD8, Joseph P. McGuirk, DO9, Caron A. Jacobson, MD10, Marie José Kersten, MD, PhD11, Irit Avivi, MD12*, Andrew Peng, MS13*, Marco Schupp, MD13*, Christina To, MD13* and Olalekan O. Oluwole, MBBS14
https://ash.confex.com/ash/2022/webprogram/Paper158303.html

766 Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
Christopher J. Ferreri, MD1, Michelle A.T. Hildebrandt, PhD1, Hamza Hashmi, MD2, Leyla O. Shune, MD3, Joseph P. McGuirk, DO4, Douglas W. Sborov, MD5, Charlotte B Wagner, PharmD6*, M. Hakan Kocoglu, MD7, Shebli Atrash, MD8, Peter M. Voorhees, MD9, Jack Khouri, MD10, Danai Dima, MD10, Aimaz Afrough, MD11, Aishwarya Sannareddy, MBBS12*, Gary Simmons, DO13, James Davis, PharmD2*, Nilesh Kalariya1*, Lauren C. Peres, PhD, MPH14*, Melissa Alsina, MD**15, Frederick L. Locke, MD16, Surbhi Sidana, MD17, Doris K. Hansen, MD18, Krina Patel, MD, MSc19 and Omar Alexis Castaneda Puglianini, MD20
https://ash.confex.com/ash/2022/webprogram/Paper164884.html

252 Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy
Lauren C. Peres, PhD, MPH1*, Laura B. Oswald, PhD2*, Christen Dillard, MD3, Gabriel De Avila, BS4*, Taiga Nishihori, MD5, Brandon J. Blue, MD6, Ciara L. Freeman, MSc, FRCPath, MBBChir, MRCP4, Frederick L. Locke, MD7, Melissa Alsina, MD**8, Omar Alexis Castaneda Puglianini, MD9, Leyla O. Shune, MD10, Douglas W. Sborov, MD11, Charlotte B Wagner, PharmD12*, Danai Dima, MD13, Hamza Hashmi, MD14, James Davis, PharmD14*, M. Hakan Kocoglu, MD15, Shebli Atrash, MD16, Gary Simmons, DO17, Nilesh Kalariya3*, Christopher J. Ferreri, MD3, Aishwarya Sannareddy, MBBS18*, Aimaz Afrough, MD19, Peter M. Voorhees, MD20, Jack Khouri, MD21, Joseph P. McGuirk, DO22, Surbhi Sidana, MD23, Doris K. Hansen, MD5 and Krina Patel, MD, MSc24
https://ash.confex.com/ash/2022/webprogram/Paper158478.html

476 Microbial Bile Acid Metabolism Shapes Effector T Cell Responses during Inflammation in Mouse and Human
Sarah Lindner, MD1*, Oriana Miltiadous, MD2*, Ruben J Ramos3*, Anqi Dai, MS1*, Anastasia Kousa, PhD1*, Gabriel K Armijo1*, Romina Ghale1*, Chi L Nguyen1*, Jenny Paredes Sanchez, PhD1*, Teng Fei, PhD4*, John W Frame V5*, Sebastien Monette, DMV, MVSc6*, Emily Fontana1*, John Slingerland7*, Ying Taur, MD, MHP5*, Marina D Burgos da Silva, PhD1*, Kate A Markey, MBBS, M Clin Res, PhD, FRACP8, Jonathan U Peled, MD, PhD9, Melody Smith, MD, MS10, Sergio A Giralt, MD9, Miguel-Angel Perales, MD11, Justin R Cross, PhD3*, Clarissa Campbell, PhD12* and Marcel R M van den Brink, MD, PhD11
https://ash.confex.com/ash/2022/webprogram/Paper167809.html

769 Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide
Amandeep Salhotra, MD1, Samer A Srour, MD, MS2, Rasmus T Hoeg, MD3*, Ayman Saad, MB/BCH4*, Everett H Meyer, MD, PhD5*, Anna Pavlova, MD, PhD6*, Edmund K. Waller, MD, PhD7, Mwe Mwe Chao, MD8*, J Scott McClellan, MD, PhD8, Nathaniel B Fernhoff, PhD8*, Robert Lowsky, MD5 and Mehrdad Abedi, MD9
https://ash.confex.com/ash/2022/webprogram/Paper170459.html

 

Stanford BMT-CT ASH Abstracts 2022: Poster Abstracts

4657 Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
Sushma Bharadwaj, MD, MS1*, Mark P Hamilton, MD2, Bita Sahaf, PhD3*, John Tamaresis, PhD4*, Sunita Patil5*, Paul J Hanson, PhD6*, Theresa Latchford, RN3*, Sally Arai, MD7, Laura J. Johnston, MD8, Robert Lowsky, MD8, Robert S. Negrin, MD8, Andrew R. Rezvani, MD9, Judith A Shizuru, MD, PhD1, Everett H Meyer, MD, PhD8*, Parveen Shiraz, MD8, Surbhi Sidana, MD10, Melody Smith, MD, MS11, Wen-Kai Weng, MD, PhD12, Lori Muffly, MD1, Crystal L. Mackall, MD13, Matthew J Frank, MD, PhD14, David B. Miklos, MD, PhD8 and Saurabh Dahiya, MD15
https://ash.confex.com/ash/2022/webprogram/Paper170759.html

 

4659 Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
Surbhi Sidana, MD1, Lauren C. Peres, PhD, MPH2*, Hamza Hashmi, MD3, Hitomi Hosoya, MD, PhD4, Christopher J. Ferreri, MD5, Shebli Atrash, MD6, Jack Khouri, MD7, Peter M. Voorhees, MD6, Danai Dima, MD8, Gary Simmons, DO9, Nilesh Kalariya5*, Vanna Hovanky10*, Sushma Bharadwaj, MD, MS11*, Sally Arai, MD12, David B. Miklos, MD, PhD11, Charlotte B Wagner, PharmD13*, James Davis, PharmD3*, Douglas W. Sborov, MD14, Taiga Nishihori, MD15, Melissa Alsina, MD**16, Frederick L. Locke, MD17, Rebecca Gonzalez, PharmD, BCOP17*, M. Hakan Kocoglu, MD18, Aishwarya Sannareddy, MBBS19*, Aimaz Afrough, MD20, Joseph P. McGuirk, DO21, Leyla O. Shune, MD21, Krina Patel, MD, MSc22 and Doris K. Hansen, MD15
https://ash.confex.com/ash/2022/webprogram/Paper166058.html

2106 Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
Shona Philip, MD1, Robert Lowsky, MD1, Laura J. Johnston, MD1, Sally Arai, MD2, Everett H Meyer, MD, PhD1*, Robert S. Negrin, MD1, Andrew R. Rezvani, MD3, Parveen Shiraz, MD1, Judith A Shizuru, MD, PhD4, Surbhi Sidana, MD5, Wen-Kai Weng, MD, PhD6, Sushma Bharadwaj, MD, MS4*, Matthew J Frank, MD, PhD7, David B. Miklos, MD, PhD1, Melody Smith, MD, MS8, Lori Muffly, MD4 and Vaibhav Agrawal, MD9
https://ash.confex.com/ash/2022/webprogram/Paper168546.html

2090 Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease
Michelle Chin, MS1, Judith A Shizuru, MD, PhD2, Lori Muffly, MD2, Parveen Shiraz, MD3, Laura J. Johnston, MD3, Robert Lowsky, MD3, Andrew R. Rezvani, MD3, Matthew J Frank, MD, PhD4, Sushma Bharadwaj, MD, MS2*, Wen-Kai Weng, MD, PhD3, Robert S. Negrin, MD2, David B. Miklos, MD, PhD2 and Sally Arai, MD5
https://ash.confex.com/ash/2022/webprogram/Paper165547.html

3358 Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
Mark P Hamilton, MD1,2,3, Felicia C Liu-Fei3*, Stefan K. Alig, MD4, John Tamaresis, PhD5*, Mohammad Shahrokh Esfahani, PhD6*, Zinaida Good, PhD3,5,7, Brian Sworder, MD, PhD8, Joseph Schroers-Martin, MD6, Chih Long Liu, PhD6*, Freja Tang Severinsen, BSc2,9*, Paul J Hanson, PhD3*, Ying Lu, PhD5*, Robert Lowsky, MD2, Robert S. Negrin, MD2, Everett H Meyer, MD, PhD2*, Melody Smith, MD, MS2, Sushma Bharadwaj, MD, MS10*, Judith A Shizuru, MD, PhD2,11, Surbhi Sidana, MD2,3, Parveen Shiraz, MD2, Andrew R. Rezvani, MD2, Laura J. Johnston, MD2, Wen-Kai Weng, MD, PhD2, Sally Arai, MD12, Lori Muffly, MD2,3, Saurabh Dahiya, MD2, Maximilian Diehn, MD, PhD13*, David M. Kurtz, MD, PhD6, Bita Sahaf, PhD3*, Crystal L. Mackall, MD3,7,14, Matthew J Frank, MD, PhD15, David B. Miklos, MD, PhD2,3 and Ash A. Alizadeh, MD, PhD11,16
https://ash.confex.com/ash/2022/webprogram/Paper165600.html

2849 Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS
Navika D. Shukla, MD1*, Joseph Schroers-Martin, MD2, Karan R. Kathuria3*, Brian Sworder, MD, PhD4, Stefan K. Alig, MD3, Matthew J Frank, MD, PhD5, David B. Miklos, MD, PhD6, Steven Coutre, MD7, Maximilian Diehn, MD, PhD8*, Michael S. Khodadoust, MD PhD3, Mark Roschewski, MD9, David M. Kurtz, MD, PhD10 and Ash A. Alizadeh, MD, PhD11
https://ash.confex.com/ash/2022/webprogram/Paper165656.html

2018 A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies
Sattva S. Neelapu, MD1, Don A. Stevens, MD2, Mehdi Hamadani, MD3, Matthew J Frank, MD, PhD4, Houston Holmes, MD, MBA5*, Aya Jacobovits, PhD6*, John Hinkle, PhD7*, Jackie Kennedy-Wilde, MS6*, Ori Maller, PhD6*, Bayarmagnai Weinstein, MD, PhD6*, Francesco Galimi, MD, PhD6, Rose K Lai, MD6* and David B. Miklos, MD, PhD8
https://ash.confex.com/ash/2022/webprogram/Paper157400.html

3345 Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel
Frederick L. Locke, MD1, Zhen-Huan Hu, MPH2*, Tanya Siddiqi, MD3, Caron A. Jacobson, MD4, Sarah Nikiforow, MD, PhD4, Sairah Ahmed, MD5, David B. Miklos, MD, PhD6, Yi Lin, MD, PhD7, Matthew A. Lunning, DO, FACP8, Brian T. Hill, MD, PhD9, Armin Ghobadi, MD10, Harry Miao, MD, PhD2*, Shilpa Shahani, MD2*, Clare Spooner, MBBS, BSc2*, Christine Fu, PhD2*, Anik R. Patel, PhD2*, Hairong Xu, MD, PhD2* and Marcelo C Pasquini, MD, MS11
https://ash.confex.com/ash/2022/webprogram/Paper155603.html

3866 Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy
Jan Boegeholz, MD1, Stefan K. Alig, MD2, Brian Sworder, MD, PhD3, Joseph Schroers-Martin, MD4, Charles Macaulay, MSc, BA5*, Alexander F. M. Craig, MD, MPhil6, Ulrich Duehrsen, MD7, Andreas Hüttmann, MD8, Jason Westin, MD9, Hua-Jay J. Cherng, MD10, David B. Miklos, MD, PhD11, Matthew J Frank, MD, PhD12, Maximilian Diehn, MD, PhD13,14*, David M. Kurtz, MD, PhD4 and Ash A. Alizadeh, MD, PhD15
https://ash.confex.com/ash/2022/webprogram/Paper170087.html

4628 Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation
Liora M. Schultz, MD1, Sneha Ramakrishna, MD2, Reema Baskar, PhD3*, Rebecca M Richards, MD, PhD4, Jennifer Moon, jmoon@stanfordchildrens.org5*, Christina Baggott, RN, PhD6*, Michelle Fujimoto7*, Michael Kunicki5*, Amy Li, ali4@stanford.edu8*, Sneha Jariwala9*, Courtney Erickson5*, Ashley Jacobs9*, Karen Yamabe10*, Valentin Barsan10*, Robbie G. Majzner, MD11, Emily L. Egeler, PhD12*, Sharon Mavroukakis13*, Zachary Ehlinger, MS14*, Warren D. Reynolds, BS14*, Bita Sahaf, PhD12*, Lori Muffly, MD15, Matthew J Frank, MD, PhD16, Anne-Louise Gramstrup17*, Harshini Chinnasamy, MS12*, Shabnum Patel, PhD3*, David B. Miklos, MD, PhD18, Steven A. Feldman, PhD12*, Crystal L. Mackall, MD19 and Kara L. Davis, D.O.20
https://ash.confex.com/ash/2022/webprogram/Paper167789.html

4199 Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
Javier Munoz, MD, MS, MBA1, Patrick M. Reagan, MD2, Andre H. Goy, MD, MS3*, David B. Miklos, MD, PhD4, Dan Zheng, PhD5*, Xiang Fang, PhD5*, Rhine R. Shen, PhD5*, Rubina Siddiqi, PhD, MBA5*, Ioana Kloos, MD, FRCPC5*, Marie José Kersten, MD, PhD6 and Michael Wang, MD7
https://ash.confex.com/ash/2022/webprogram/Paper158097.html

4677 Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
Jack Khouri, MD1, Hong Li, MS2*, Doris K. Hansen, MD3, Surbhi Sidana, MD4, Leyla O. Shune, MD5, Shaun DeJarnette6*, Faiz Anwer, MD1*, Douglas W Sborov7*, Charlotte B Wagner, PharmD7*, M. Hakan Kocoglu, MD8, Shebli Atrash, MD9, Peter M. Voorhees, MD10, Jason Valent, MD1, Lauren C. Peres, PhD, MPH11*, Vanna Hovanky12*, Gary Simmons, DO13, Danai Dima, MD1, Nilesh Kalariya14*, Aimaz Afrough, MD15, Gurbakhash Kaur, MD16*, Aishwarya Sannareddy, MBBS17*, Christopher J. Ferreri, MD14, James Davis, PharmD18*, Joseph P. McGuirk, DO19, Frederick L. Locke, MD20, Rachid C. Baz, MD21, Betty K. Hamilton, MD22, Melissa Alsina, MD**23, Craig S. Sauter, MD24*, Hamza Hashmi, MD18 and Krina Patel, MD, MSc25
https://ash.confex.com/ash/2022/webprogram/Paper163464.html

2027 Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
Hamza Hashmi, MD1, Doris K. Hansen, MD2, Lauren C. Peres, PhD, MPH3*, Omar Alexis Castaneda Puglianini, MD4, Ciara L. Freeman, MSc, FRCPath, MBBChir, MRCP4, Gabriel De Avila, BS4*, Surbhi Sidana, MD5, Leyla O. Shune, MD6, Douglas W. Sborov, MD7, James Davis, PharmD1*, Charlotte B Wagner, PharmD8*, M. Hakan Kocoglu, MD9, Shebli Atrash, MD10, Peter M. Voorhees, MD11, Gary Simmons, DO12, Christopher J. Ferreri, MD13, Nilesh Kalariya13*, Aishwarya Sannareddy, MBBS14*, Danai Dima, MD15, Jack Khouri, MD16, Joseph P. McGuirk, DO17, Frederick L. Locke, MD18, Rachid C. Baz, MD19, Krina Patel, MD, MSc20 and Melissa Alsina, MD**21
https://ash.confex.com/ash/2022/webprogram/Paper164828.html

2019 Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Sham Mailankody, MBBS 1, Jeffrey V. Matous, MD2, Michaela Liedtke, MD3, Surbhi Sidana, MD4, Olalekan O. Oluwole, MBBS5, Meera Mohan, MD, MS6*, Jose C. Cruz, MD7, Rajneesh Nath, MD8, Faiz Anwer, MD9*, Adriana Rossi, MD, MSc10, Myo Htut, MD11, Shahbaz A. Malik, MD12, Srinivas Ghatta, PhD13*, Myles Dillon, PhD13*, Wendy Ying, PhD13*, Lynn Navale, MS13*, Erin E. Karski, MD13*, Arun Balakumaran, MD13 and Shaji K Kumar, MD14
https://ash.confex.com/ash/2022/webprogram/Paper158231.html

3414 Subsequent Solid Neoplasms Following Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies: Comparing Center for International Blood and Marrow Transplant Research (CIBMTR) and California Cancer Registry (CCR) Data
Sara J. Schonfeld, PhD1*, Bryan Valcarcel, MD1*, Christa L. Meyer, MS2*, Ann M Brunson, MS3*, Julianne J.P. Cooley, MS4*, Renata Abrahao, MD, PhD, MSc3, Ted Wun, MD3, Jeffery Auletta, MD2,5*, Lori Muffly, MD, MS6, Theresa H.M. Keegan, PhD3 and Lindsay M. Morton, PhD1
https://ash.confex.com/ash/2022/webprogram/Paper159010.html

3421 Comparison of Vital Status and Cause-Specific Mortality after Hematopoietic Cell Transplantation between the Center for International Blood and Marrow Transplant Research and the California Cancer Registry: A Record-Linkage Analysis from 1991 to 2018
Bryan Valcarcel, MD1*, Sara J. Schonfeld, PhD1*, Christa L. Meyer, MS2*, Ann M Brunson, MS3*, Julianne J.P. Cooley, MS4*, Renata Abrahao, MD, PhD, MSc3, Ted Wun, MD3, Jeffery Auletta, MD2,5*, Lori Muffly, MD, MS6, Theresa H.M. Keegan, PhD3 and Lindsay M. Morton, PhD1
https://ash.confex.com/ash/2022/webprogram/Paper160330.html

2275 Interim Update on the ‘Watch’ Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies
Krish Patel, MD1, Jakub Svoboda, MD2, Bijal D. Shah, MD3, Bruce D. Cheson, MD4, Georges Azzi, MD5*, Kashyap Patel, MD6*, Andrew J Cowan, MD7, Lori Muffly, MD8, Heidi Simmons, PhD9, Mark Schliekelman, PhD9* and Jessica Leonard, MD10
https://ash.confex.com/ash/2022/webprogram/Paper167669.html

4520 Utilization of Autologous HCT in Multiple Myeloma: A Novel Linkage of CIBMTR, Cancer Registry and Hospitalization Data in California
Naseem S Esteghamat, MD, MS1, Ann M Brunson, MS2*, Ted Wun, MD3, Aaron S Rosenberg, MD1, Julianne J.P. Cooley, MS4*, Sara J. Schonfeld, PhD5*, Christa L. Meyer, MS6*, Bryan Valcarcel, MD5*, Renata Abrahao, MD, PhD, MSc7, Jeffery Auletta, MD8,9, Lindsay M. Morton, PhD5, Lori Muffly, MD10 and Theresa H.M. Keegan, PhD7
https://ash.confex.com/ash/2022/webprogram/Paper159776.html

3621 Real World Outcomes in Acute Myeloid Leukemia Patients Following Post Hematopoietic Stem-Cell Transplantation Maintenance Treatment with Midostaurin or Sorafenib: A US Retrospective Cohort Study
Lori Muffly, MD, MS1, Christopher Young, PhD2*, Bin Xie, PhD2*, Alana Block, PharmD3*, Maelys Touya, PharmD3* and Bhavik J. Pandya, PharmD2*
https://ash.confex.com/ash/2022/webprogram/Paper157964.html

3408 Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T
Everett H Meyer, MD, PhD1*, M Scott Killian, PhD2*, Anna Pavlova, MD, PhD3*, Cameron Bader3*, Sean Summers2*, Fernando Teque2*, J Scott McClellan, MD, PhD2 and Nathaniel B Fernhoff, PhD2*
https://ash.confex.com/ash/2022/webprogram/Paper164468.html

4719 The Prevalence and Effects of Frailty in Chronic Graft-Versus-Host Disease
Nahid Rashid, MD1,2, Mukta Arora, MD3, Paul A. Carpenter, MD4, Amin M Alousi, MD5, Betty K. Hamilton, MD6, Joseph Pidala, MD, PhD7, Lynn E. Onstad, ScM4*, Corey Cutler, MD, MPH, FRCPC8, Mary E. D. Flowers, MD1, Sally Arai, MD9, Smita Bhatia, MD, MPH10 and Stephanie J. Lee, MD, MPH4
https://ash.confex.com/ash/2022/webprogram/Paper167901.html

4767 Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia
Shlomo Elias, MD, PhD1*, Moneeza Walji, MD, BSc, MPH2, Samantha Brown, MS3*, Sean M. Devlin, PhD4*, Esperanza B. Papadopoulos, MD5,6, Ann A Jakubowski, MD PhD5,6, Doris M. Ponce, MD6,7, James W. Young, MD8, Sergio A Giralt, MD9,10, Miguel-Angel Perales, MD6,11, Brian C. Shaffer, MD5,6, Parastoo B. Dahi, MD6,12, Richard J. Lin, MD6,11, Christina Cho, MD5,6, Roni Tamari, MD6,13, Melody Smith, MD, MS14,15 and Boglarka Gyurkocza, MD5,6
https://ash.confex.com/ash/2022/webprogram/Paper170088.html

3335 A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Miguel-Angel Perales, MD1, Sairah Ahmed, MD2, Saurabh Dahiya, MD3, Peter A. Riedell, MD4, Joseph P. McGuirk, DO5, Olalekan O. Oluwole, MBBS6, Sohail A. Chaudhry, MD7*, Zachary Lee, PharmD7*, Stanley Dai7*, Neha Dixit, PhD7*, Christie Fanton, PhD7*, Mario Q. Marcondes, MD, PhD7, Jonathan Zalevsky, PhD7*, Mary A. Tagliaferri, MD7* and Cameron J. Turtle, MBBS, PhD8
https://ash.confex.com/ash/2022/webprogram/Paper162511.html

2032 Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
Arushi Khurana, MBBS1, Megumi Bailey, MSc2*, Madiha Iqbal, MD3, Radhika Bansal, MBBS1*, Catherine J. Lee, MD4, Bradley Hunter, MD, MPH5, Matthew A. Lunning, DO, FACP6, Samantha Jaglowski, MD, MPH7, Michael D. Jain, MD, PhD8, Saurabh Dahiya, MD9, Veronika Bachanova, MD, PhD10, Umar Farooq, MD11, Sairah Ahmed, MD12, Brian T. Hill, MD, PhD13, Javier L Munoz, MD, MBA14*, Krish Patel, MD15, Olalekan O. Oluwole, MBBS16 and Yi Lin, MD, PhD17
https://ash.confex.com/ash/2022/webprogram/Paper170486.html

4287 Clinical Outcomes of CD19 CAR-T-Cell Therapy with Axi-Cel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) with and without Prior Autologous Stem Cell Transplant
David Tong Chen, MD1*, Olga Goloubeva, PhD, MSc2*, Hanan Alkhaldi, MD3*, Aaron P. Rapoport, MD3, Saurabh Dahiya, MD4, Nancy M. Hardy, MD3, Djordje Atanackovic, MD3, Mehmet Hakan Kocoglu, MD3, Forat Lutfi, MD3 and Jean A. Yared, MD5
https://ash.confex.com/ash/2022/webprogram/Paper158281.html

2278 Long-Term Cognitive and Neuropsychiatric Outcomes in Adults Who Have Received Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - a Pilot Feasibility Study
Brian J Scott, MD1*, Tracy Murray, NP2*, Gayle K Deutsch, PhD, ABPP2*, Sheila Lahijani, MD3*, Matthew J Frank, MD, PhD4 and Michelle Monje, MD, PHD5*
https://ash.confex.com/ash/2022/webprogram/Paper168229.html

2872 Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma
Tanaya Shree, MD, PhD1, Sarah Haebe, MD1*, Debra K. Czerwinski2, Erik Eckhert, MD, MS3, Grady Day1*, Anuja Sathe, MD, PhD1*, Susan M. Grimes, BSc4*, Matthew J Frank, MD, PhD5, Lauren S. Maeda, MD6*, Ash A. Alizadeh, MD, PhD7, Ranjana H. Advani, MD8, Richard Hoppe, MD9, Steven R. Long, MD10*, Brock Martin, MD11*, Michael G. Ozawa, MD, PhD11*, Michael S. Khodadoust, MD PhD12, Hanlee P. Ji, MD1* and Ronald Levy, MD1
https://ash.confex.com/ash/2022/webprogram/Paper167469.html

 

ASH SCIENTIFIC WORKSHOP

CAR T-Cells and the Gut Microbiome

Scientific Workshop on Bedside to Bench: Dissecting Emergent CAR T-cell Toxicities beyond CRS and ICANS
Scientific Workshops
Session: CAR T-cell Toxicities and Associations with Cytokine Profiling and the Gut Microbiome

Friday, December 9, 2022, 3:00 PM-4:00 PM

271-273 (Ernest N. Morial Convention Center)

Melody Smith, MD, MS

https://ash.confex.com/ash/2022/webprogram/Paper171531.html